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Abstract: Introduction Autosomal dominant tubulo-interstitial kidney disease due to UMOD mutations
(ADTKD-UMOD) is a rare condition associated with high variability in the age of end-stage kidney
disease (ESKD). The minor allele of rs4293393, located in the promoter of the UMOD gene, is present in
19% of the population and downregulates uromodulin production by approximately 50% and might affect
the age of ESKD. The goal of this study was to better understand the genetic and clinical characteristics
of ADTKD-UMOD and to perform a Mendelian randomization study to determine if the minor allele of
rs4293393 was associated with better kidney survival. Methods An international group of collaborators
collected clinical and genetic data on 722 affected individuals from 249 families with 125 mutations,
including 28 new mutations. The median age of ESKD was 47 years. Men were at a much higher risk of
progression to ESKD (hazard ratio 1.78, P < 0.001). Results The allele frequency of the minor rs4293393
allele was only 11.6% versus the 19% expected (P < 0.01), resulting in Hardy-Weinberg disequilibrium
and precluding a Mendelian randomization experiment. An in vitro score reflecting the severity of the
trafficking defect of uromodulin mutants was found to be a promising predictor of the age of ESKD.
Conclusion We report the clinical characteristics associated with 125 UMOD mutations. Male gender
and a new in vitro score predict age of ESKD.
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Introduction: Autosomal dominant tubulo-interstitial kidney disease due to UMOD mutations (ADTKD-
UMOD) is a rare condition associated with high variability in the age of end-stage kidney disease (ESKD).
The minor allele of rs4293393, located in the promoter of the UMOD gene, is present in 19% of the pop-
ulation and downregulates uromodulin production by approximately 50% and might affect the age of
ESKD. The goal of this study was to better understand the genetic and clinical characteristics of ADTKD-
UMOD and to perform a Mendelian randomization study to determine if the minor allele of rs4293393 was
associated with better kidney survival.
Methods: An international group of collaborators collected clinical and genetic data on 722 affected in-
dividuals from 249 families with 125 mutations, including 28 new mutations. The median age of ESKD was
47 years. Men were at a much higher risk of progression to ESKD (hazard ratio 1.78, P < 0.001).
Results: The allele frequency of the minor rs4293393 allele was only 11.6% versus the 19% expected (P <
0.01), resulting in Hardy-Weinberg disequilibrium and precluding a Mendelian randomization experiment.
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An in vitro score reflecting the severity of the trafficking defect of uromodulin mutants was found to be a
promising predictor of the age of ESKD.
Conclusion: We report the clinical characteristics associated with 125 UMOD mutations. Male gender and
a new in vitro score predict age of ESKD.
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T
he cardinal manifestations of ADTKD-UMOD
include autosomal dominant inheritance, preco-
cious gout in some individuals, and slowly progressive
chronic kidney disease.1 Progression to ESKD is vari-
able, occurring between ages 20 and 70 years.2–5 The
reasons for this variation are unknown. Identification
of the causes would lead to a better understanding of
the pathogenesis of ADTKD-UMOD, identify in-
dividuals at risk of progression for clinical trials, and
provide information about prognosis for patients.
In ADTKD-UMOD, retention of mutant uromodulin
(mUMOD) protein in the endoplasmic reticulum (ER) of
tubular epithelial cells in the thick ascending limb leads
to ER stress, tubular cell death, and chronic kidney
disease.4,6–11 Uromodulin has a high cysteine content,
resulting in a slow transit through the ER as disulfide
bonds form.12 Approximately two-thirds of the muta-
tions causing ADTKD-UMOD (mUMOD) involve cysteine
residues, and no mutations have been found resulting in
truncation or loss of transcription.4 Umod knockout mice
also do not develop the ADTKD phenotype.13 These
findings implicate mUMOD as the principal pathophys-
iologic cause of ADTKD-UMOD. Based on these hy-
potheses, one could theorize the amount of mUMOD
expressed and the type of mutation may contribute to the
pathophysiology and age of ESKD onset.
Figure 1. Genetic map of rs4293393 and UMOD with a representative autosomal dominant tubulo-interstitial kidney disease due to UMOD
mutations (ADTKD-UMOD) pedigree demonstrating rs4293393-UMOD haplotype inheritance. (a) Genetic map of rs4293393 and UMOD, showing
the linkage disequilibrium of rs4293393 with the UMOD mutations (mUMODs) found in this cohort study; 124 of 125 mUMODs occurred in exons 3
and 4 and were in a region of complete linkage disequilibrium with rs4293393. (b) Representative 4-generation ADTKD-UMOD pedigree.
Genetically affected individuals are represented by black symbols, and the rs4293393-mUMOD haplotype is shaded gray. The rs4293393 allele (in
this case “A”) is in phase with the mUMOD (designated m). In all genetically affected family members (due to linkage disequilibrium of rs4293393
and the UMOD gene [A]), the rs4293393-mUMOD haplotype is inherited together. In contrast, the rs4293393–wild-type UMOD (designated WT)
haplotype inherited from the unaffected parent varies in subsequent generations based on the rs4293393-WT UMOD haplotypes of the unaf-
fected parent. gDNA, genomic DNA; SNP, single nucleotide polymorphism; UTR, untranslated region.
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There is a genetic variant (known as single nucleotide
polymorphism [SNP] rs4293393) present in the UMOD
promoter (Figure 1a). In 19% of Europeans, this SNP has a
guanosine residue and results in an approximately 50%
reduction in uromodulin expression as compared with the
remaining 81% of the European population, which has an
adenosine residue at this site.14 As rs4293393 resides in the
promoter of the UMOD gene, it is virtually always
inherited together with the UMOD gene on the same allele.
Indeed, UMOD promoter variants are within a region of
complete linkage disequilibrium that spans exons 1 to 5.
Because more than 95% of UMOD mutations are within
exons 3 and 4, this implies that for virtually all pedi-
grees the variants in the UMOD promoter and the causal
UMOD mutation cosegregate. In a given family with
ADTKD-UMOD, all affected individuals who inherit the
mUMOD gene will inherit the same rs4293393 allele
adjacent to mUMOD (Figure 1b). The rs4293393 variant
that is present on the wild-type allele will be inherited
from the unaffected parent and will not be the same for
all affected family members (Figure 1b).
The primary aims of this investigation were to better
characterize the genetic and clinical findings of ADKTD-
UMOD in a large population of affected families and to
perform a Mendelian randomization study of individuals
affected with ADTKD-UMOD. In a Mendelian randomiza-
tion study, one studies the effects of genetic variants
randomly distributed in a population on an outcome (e.g.,
kidney failure). We hypothesized that the presence of the
minor rs4293393 variant in the promoter of the mUMOD
allele would lead to a decreased expression of mUMOD.
Thus, families with the minor rs4293393 variant in the
mUMOD promoter should have decreased expression of
mUMOD, which might ameliorate mutant protein deposi-
tion, preserve the tubulo-interstitium, and slow progression
of chronic kidney disease and development of ESKD. This
decreased production of mUMOD would be similar to the
administration of a medication from birth onward (with
100% compliance) that lowers mUMOD production by
approximately 50%. Our goal was to determine if the
presence of the rs4293393 minor SNP variant with the
mUMOD allele results in a later age of onset of ESKD.
Another factor that could affect the age of ESKD
onset is the nature of the mUMOD mutation and its
effect on the transit of uromodulin and mUMOD
through the ER and on apoptosis. Some mutations may
have a more deleterious effect on uromodulin traf-
ficking and consequently ER function.7,15 To this end,
we quantified the mUMOD trafficking defect for 35
selected mutations (Supplementary Table S1) through
an in vitro score and investigated whether this score
correlated with the age of onset of ESKD.
The dataset included genetic information and age of
ESKD from 12 international ADTKD research teams
(international cohort), as well as the Wake Forest ADTKD
registry (WF cohort), which included additional clinical
information (Figure 2). The data from the WF cohort and
from the international cohort were combined to analyze
genetic factors and gender, and the WF cohort data were
then further analyzed to explore other factors that could
affect the age of ESKD, including body mass index,
smoking status, presence of gout, age of gout onset, and
the mean age of ESKD for family members.
METHODS
The study was approved by the Wake Forest School of
Medicine Institutional Review Board, all institutional
review boards of participating centers, and was carried
out in accordance with the Declaration of Helsinki.
Recruitment
(i) Most participants were from the WF cohort16 (Figure 2).
Families were either referred by their physician or self-
referred by a family member. A genetic diagnosis was
made in the index case and then in as many family
members as possible. A family tree was constructed that
included the age of onset of ESKD in both living and
deceased family members. A questionnaire containing
demographic and clinical information was completed by as
many affected family members as possible. (ii) Data ob-
tained from affected individuals and families from the
international cohort included the UMOD mutation,
rs4293393 genotype when available, gender, and current
kidney function or age of ESKD onset.
Genetic Evaluation
An index case in each family underwent mutational
analysis and was found to have a UMOD mutation as
described in the Supplementary Methods. As many
family members as possible then underwent genetic
testing for the at-risk UMOD mutation. Individuals
found to be genetically affected underwent rs4293393
genotyping (Supplementary Methods).
In 209 of 240 families, genetic linkage was used to
identify which of the rs4293393 alleles was present in
the promoter of the mUMOD allele. In 18 families in
whom DNA was available, the phase of the rs4293393
allele and mUMOD was established via cloning, geno-
typing, and sequencing of long-range polymerase chain
reaction products encompassing the promoter and
UMOD genomic sequence (Supplementary Methods). If
the genotype and phase of the rs4293393 variant were
established in at least 1 affected family member, it was
assumed that all affected family members had the same
rs4293393 variant, given the very high linkage
disequilibrium. All available family members under-
went rs4293393 variant testing to determine if results
were consistent.
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DNA could not be obtained on some family mem-
bers, most often because they were deceased. In-
dividuals were considered historically affected if they
met the following criteria: (i) a DNA sample for genetic
diagnosis could not be obtained; (ii) there was a clinical
history of at least chronic kidney disease stage 3
(estimated glomerular filtration rate <60 ml/min per
1.73 m2) that was consistent with ADTKD-UMOD; and
(iii) the familial inheritance pattern was consistent with
the individual being genetically affected.
In Vitro Score Determination
See Supplementary Methods for a full description. Thirty-
five UMOD mutations were selected based on cohort
prevalence and affected families having the youngest and
oldest mean ages of ESKD onset. MDCK and/or HEK293
cell lines were transfected with expression vectors for each
selected mUMOD and cell lysates analyzed by Western
blots to evaluate uromodulin trafficking defects. UMOD
mutation scoring was performed by quantifying the ratio
between low- and high-molecular weight uromodulin
glycoforms in 3 independent experiments.
Statistical Analysis
Descriptive statistics are shown as counts and pro-
portions for categorical variables and mean  SD for
continuous variables. For each variable, comparisons
between WF and international cohorts were made us-
ing c2 and Fisher’s exact tests for categorical variables
and Wilcoxon rank-sum tests for continuous variables.
Testing for Hardy-Weinberg equilibrium was per-
formed by adopting bootstrapping resampling methods
with 1000 repeated sampling on the cohort subsets to
estimate variance for the minor allele frequency.
A pedigree structure was built using Sequential
Oligogenetic Linkage Analysis Routines (SOLAR) soft-
ware (http://solar-eclipse-genetics.org) based on the
reported family trees and used to create a kinship matrix
with the R package “kinship2” (https://cran.r-project.
org/web/packages/kinship2/kinship2.pdf). Survival
analysis was then performed with the outcome being age
of ESKD (defined as starting dialysis, receiving a kidney
transplant, or dying from kidney failure without
receiving dialysis). Individuals were censored if they




































Figure 2. Flow diagram showing contribution of the Wake Forest and International cohorts to the development of the autosomal dominant
tubulo-interstitial kidney disease due to UMOD mutations (ADTKD-UMOD) registry. A total of 929 individuals underwent genetic testing and 722
were documented to have a UMOD mutation (UMOD genetically affected), and 633 underwent further genetic testing for rs4293393. Historically
affected individuals were from families genetically diagnosed with ADTKD-UMOD but in whom a DNA sample was unavailable. These in-
dividuals suffered from at least chronic kidney disease stage 3 and clinical findings were consistent with ADTKD-UMOD. Clinical information
was available in most individuals from the Wake Forest cohort. In vitro scores were developed for 35 UMOD mutations to further understand
disease progression.
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Table 1. Characteristics of individuals with ADTKD-UMOD who were genetically or historically affected, by cohort
Characteristic
WF cohort
International cohort P valueADTKD-UMOD genotyped ADTKD-UMOD historic All
ADTKD-UMOD genotyped n ¼ 400 400 (61%) 322 (98%)
ADTKD-UMOD historic n ¼ 254 254 (39%) 7 (2%)









Age of ESKD 46.37 51.17 48.65 48.88 0.88
Male gender, n (%) 180 (48) 145 (57) 325 (50) 162 (49)
2 (1) unknown
0.20b
Race, n (%) <0.0001b
White 380 (95) 247 (97) 627 (96) 271 (82)
Black 3 (1) 0 3 (0.5) 0
Hispanic 0 0 0 0
Asian/Pacific Islander 11 (3) 5 (2) 16 (2) 0
From India 1 (0.3) 1 (0.4) 2 (0.3) 0
Other 0 0 0 0
Unreported 5 (1) 1 (0.4) 6 (1) 58 (18)
Ethnicity, n (%) <0.0001b
Hispanic or Latino 6 (2) 0 6 (1) 24 (7)
Not Hispanic or Latino 374 (94) 239 (94) 613 (94) 251 (76)
Other 8 (2) 5 (2) 13 (2) 0
Unreported 12 (3) 10 (4) 22 (3) 54 (16)
Smoking, n (%) <0.0001a,c
Never 228 (57) 8 (3) 236 (36)
Current 23 (6) 1 (0.4) 24 (4)
Former 69 (17) 5 (2) 74 (11)
Uncertain 80 (20) 240 (94) 320 (49)
Weight (kg) 0.24c
Male and female 76.9  19.9 (n ¼ 287) 83.0  22.2 (n ¼ 20) 77.3  20.2 (n ¼ 307)
Male 86.3  19.2 (n ¼ 127) 87.9  18.4 (n ¼ 11) 86.4  19.1 (n ¼ 138)
Female 69.4  17.1 (n ¼ 160) 77.0  25.9 (n ¼ 9) 69.8  17.6 (n ¼ 169)
Height (cm) 0.56c
Male and Female 169.5  12.0 (n ¼ 287) 170.9  10.0 (n ¼ 20) 169.6  11.8 (n ¼ 307)
Male 177.5  11.8 (n ¼ 127) 177.1  6.3 (n ¼ 11) 177.4  11.5 (n ¼ 138)
Female 163.2  7.5 (n ¼ 160) 163.4  8.4 (n ¼ 9) 163.2  7.5 (n ¼ 169)
BMI (kg/m2) 26.5  5.8 (n ¼ 286) 28.15  6.4 (n ¼ 20) 26.6  5.8 (n ¼ 306) 0.27c
Gout, n (%) <0.0001a,c
Yes
Male and female 202 (50) 43 (17) 245 (37)
Male 106 (59) 31 (21) 137 (42)
Female 96 (44) 12(11) 108 (33)
No
Male and female 189 (47) 13 (5) 202 (31)
Male 72 (40) 6(4) 78 (24)
Female 117 (53) 7(6) 124 (38)
Uncertain
Male and female 9 (2) 198 (78) 207 (32)
Male 2 (1) 108 (7) 110 (34)
Female 7 (3) 90 (83) 97 (29)
Age of gout onset (y) 0.15c
Male and female 30.5  11.5 (n ¼ 197) 27.2  9.5 (n ¼ 20) 30.2  11.4 (n ¼ 217)
Male 29.1  9.9 (n ¼ 105) 28.2  10.4 (n ¼ 13) 29.0  9.9 (n ¼ 118)
Female 32.2  12.9 (n ¼ 92) 25.4  8.0 (n ¼ 7) 31.7  12.7 (n ¼ 99)
Mutation type, n (%)
p.H177-R185del (18%) 108 (27) 65 (26) 173 (26) 0
p.V93-G97delinsAASC (8%) 42 (10) 30 (12) 72 (11) 2 (1)
p.R178P (5%) 21 (5) 27 (11) 48 (7) 0
p.C106F (5%) 26 (6) 21 (8) 47 (7) 0
p.C148Y (3%) 12 (3) 11 (4) 23 (4) 2 (1)
p.G88D (2%) 0 0 0 23 (7)
(Continued on next page)
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developing ESKD. Cox mixed effects models were built
with the R package “coxme” (https://cran.r-project.org/
web/packages/coxme/coxme.pdf) to incorporate the
kinship matrix as the correlation structure and adjust
for familial relationships. Univariate models were
created for all parameters. Significant predictors from
the univariate models were used develop a best-fit
multivariate model. Because of the absence of some
data for individual variables (for example, parental age
of ESKD), variables were included in modeling only if
100 events had occurred to protect the robustness of the
data. This modeling adjusted for variable family sizes.
The multivariate model was created in a forward step-
wise manner with entry criteria of a P value <0.05. The
model that resulted in the highest C-statistic was
considered the most effective model.
RESULTS
In the WF cohort, 580 individuals from families with
ADTKD-UMOD underwent genotyping, with 180 of 580
(31%) individuals being genetically unaffected and 400 of
580 (69%) individuals being genetically affected
(Figure 2). There were 61 unique mutations in 129 families.
An additional 254 individuals were considered historically
affected, meaning that individuals were known to have
ADTKD-UMOD as demonstrated by clinical findings and
inheritance but did not undergo genotyping because they
were deceased or otherwise unavailable to provide a DNA
sample. The remaining data concern only individuals who
were genetically affected or historically affected. Infor-
mation regarding smoking history, body mass index,
gout, and parental age of ESKD were available only in the
WF cohort (Table 1).
For the international cohort, 349 individuals were
screened from 120 affected families. There were 322 geneti-
cally affected, 27 genetically unaffected, and 7 historically
affected. Table 1 compares characteristics of the 2 cohorts.
There was a total of 722 individuals from 249 families
affected with ADTKD-UMOD, with 125 unique mUMOD
mutations, including 28 mutations not previously
described. Of the mutations, 117 (94%) were in exon 3, 7
(6%) in exon 4, and 1 in exon 7; 47% of mutations
resulted in the loss of a cysteine residue, 6% in the gain
of a cysteine residue, and 6% resulted in a gain in hy-
drophobicity. Characteristics of individuals affected with
the most common UMOD mutations are listed in Table 2
and Supplementary Table S1 for all mutations. This table
is updated regularly at http://j.mp/2q7Fi8f. The median
age of ESKD for the entire cohort was 47 years (range 18–
87) and mean age 48.7  12.7 years. Gender had a
marked association with earlier age of ESKD (Figure 3),
with an odds ratio of 1.78 (P ¼ 0.00028). ESKD was
uncommon before age 30, with approximately 50% of
the male cohort reaching ESKD between 30 and 50, and
50% of the female cohort reaching ESKD between 30 and
60. In the WF cohort, 55% (245 of 447) of patients with
ADTKD-UMOD developed gout. Figure 4 shows a sur-
vival curve with event defined as onset of gout for in-
dividuals with gout in whom an age of gout onset was
known. The median age of gout onset was 28 years, with
gout most commonly developing between ages 15 and
40. Of 180 men with information available, 106 (59%)
developed gout at a mean age of 29.1  9.9 years. Of 220
women with information available, 96 (44%) developed
gout at a mean age of 32.2  12.9 years.
Genetic Analysis
Genetic analysis was performed on both the WF and
international cohorts, including 929 individuals from
249 families with 125 distinct UMOD mutations.
Supplementary Table S1 shows a complete list of the
number of individuals with each mutation, the median
age and range of ESKD, and the in vitro score. A family
was defined as a group of individuals from which 1
individual was referred, and in whom there were no
family members known related to other referred fam-
ilies at the time of referral. The most common mUMOD
was p.H177_R185del, with 173 individuals and 25
families from the WF cohort. The second most common
mUMOD was p.V93_G97delinsAASC with 74 in-
dividuals and 11 families. This mutation originated in
England.17 The statistical analysis performed (see
Methods) adjusted for the large number of family
members.
Table 1. (Continued) Characteristics of individuals with ADTKD-UMOD who were genetically or historically affected, by cohort
Characteristic
WF cohort
International cohort P valueADTKD-UMOD genotyped ADTKD-UMOD historic All
p.P236L (2%) 10 (2) 7 (3) 17 (3) 3 (1)
p.C135Y (2%) 14 (4) 3 (1) 17 (3) 0
p.S91del (2%) 0 1 (0.4) 1 (0.2) 16 (5)
p.P236R (1%) 3 (1) 1 (0.4) 4 (1) 5 (2)
Other mutation (54%) 164 (41) 88 (35) 252 (39) 278 (84)
ADTKD-UMOD, autosomal dominant tubulo-interstitial kidney disease due to UMOD mutations; BMI, body mass index; ESKD, end-stage kidney disease; WF, Wake Forest.
aChi-squared test.
bFisher’s exact test.
cWF genotyped versus historic.
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Genotyping of rs4293393 was performed in 633 of
722 genetically affected individuals and in 64 of 207
genetically unaffected individuals (Figure 2). With the
aid of long-range sequencing in 18 families, it was
possible to determine whether the minor or major allele
was in phase with mUMOD in 614 individuals and 227
of 240 families. In 614 of 614 cases, rs4293393 testing
results were consistent with inheritance of the same
rs4293393-mUMOD haplotype throughout each family.
In 348 individuals (92 genetically affected and 256
historically affected) who were not rs4293393 geno-
typed, the allele in phase with mUMOD was assigned
based on familial results.
Distribution of the rs4293393 SNP Variant in
Families With ADTKD-UMOD
When performing a Mendelian randomization
study, one must first determine that the genetic
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p.H177_R185del 3 25 173 46 20–87 25 0 0
p.V93_G97delins
AASC
2 11 74 48 27–75 10 0 1
p.R178P 4 9 48 53 39–79 8 0 1
p.C106F 1 11 47 55 35–72 11 0 0
p.C148Y 4 4 25 44 25–66 4 0 0
p.G88D 1 8 23 65.5 55–76 7 0 1
p.P236L 3 4 20 45 43–67 4 0 0
p.C135Y 4 2 17 41 37–47 2 0 0
p.S91del 2 5 17 50 37–66 5 0 0
p.P236R 4 5 9 40 24–50 4 0 1
ESKD, end-stage kidney disease.
Range of ESKD is earliest and latest ages of ESKD.
Figure 3. End-stage kidney disease (ESKD) survival according to gender in autosomal dominant tubulo-interstitial kidney disease due to UMOD
mutations (ADTKD-UMOD). This analysis included 675 individuals with ADTKD-UMOD with known gender and clinical information. An event was
defined as starting dialysis, receiving a transplant, or dying of kidney failure. Censoring occurred for death before ESKD or if the individual had not
reached ESKD by the end of the study period. ESKD rarely occurred before age 30, with most patients requiring dialysis by age 70. Male gender
was associated with an increased risk of reaching ESKD at an earlier age (hazard ratio 0.562, 0.00028). ESRD, end-stage renal disease.
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variant under study is randomly distributed in the
population being investigated. Approximately 19%
of the European population has the minor
rs4293393 allele (G) (defined as the minor allele
frequency [MAF]).14 In patients with ADTKD-
UMOD, for the rs4293393 allele inherited from the
unaffected parent, the MAF was 0.17, which is
similar to reference populations (Table 3). We then
sought to determine if the rs4293393 minor variant
linked to the mUMOD allele was distributed in the
same proportion as the general population. As some
of the families under study might be distantly
related, we assumed that all individuals with the
same rs4293393-mUMOD haplotype were one fam-
ily. Using this approach, there were 123 families
with the major rs4293393 allele linked to mUMOD
and 24 families with the minor rs4293393 allele
linked to mUMOD. For 9 mUMODs, there were
families with the minor allele-mUMOD haplotype
and also families with the major allele-mUMOD
haplotype. For the rs4293393 variant linked to
-mUMOD, the MAF was only 0.12 versus the MAF
of 0.19 to 0.20 in the TOPMED, gnomAD, and 1000
genome populations, which statistically deviated
from expected proportions (P ¼ 0.0037, Table 3). In
other words, the SNP minor allele, associated with
Figure 4. Survival curve of gout onset in individuals with autosomal dominant tubulo-interstitial kidney disease due to UMOD mutations (ADTKD-
UMOD). This analysis included only 219 individuals who developed gout. An event was defined as age to onset of gout. Gout rarely occurred
before age 15, with the vast majority of affected individuals developing gout between the ages of 20 and 40.







comparison group P value
rs4293993 in phase with mUMOD 1 per haplotype present in cohort 129a 0.1163 (G, A) TOPMED 0.18639 0.0147
gnomAD 0.1924 0.0082
1000 genomes 0.20 0.0037
rs4293993 out of phase with mUMOD UMOD genotyped, rs4293393 genotyped 554 0.1645 (G, A) TOPMED 0.18639 0.2693
gnomAD 0.1924 0.1629
1000 Genomes 0.20 0.07958
MAF, minor allele frequency.
aThere were 129 unique rs4293393/mUMOD haplotypes.
Conservative testing was used, in which it was assumed that all individuals with the same rs4293393-mUMOD haplotype were related. The MAF of the test population was compared
with the MAF found in TOPMED, gnomAD, and 1000 genomes registries.18 All comparisons showed that the MAF deviates from expected population frequencies. The MAF was then
determined in available samples for the UMOD allele that was inherited from the unaffected parents. This allele was found to have similar allele frequencies as the control populations.
K Kidd et al.: Predictors of Progression in ADTKD-UMOD CLINICAL RESEARCH
Kidney International Reports (2020) 5, 1472–1485 1479
lower uromodulin production, is underrepresented
when associated with mUMOD mutation, whereas
this is not the case when it is associated with a
wild-type UMOD allele. Given that the rs4293393
variant was not randomly distributed in this pop-
ulation, a Mendelian randomization experiment
could not be performed.
ESKD Survival by rs4293393 Allele
Figure 5 shows the ESKD survival curves for in-
dividuals according to the rs4293393-mUMOD
haplotype. There were 699 (94.5%) genotyped and
historic individuals with the major allele (A) in phase
with mUMOD and 41 (5.5%) genotyped and historic
individuals with the minor rs4293393 allele (G) in
Figure 5. Survival curves according to the rs4293393 allele in phase with mutant UMOD (mUMOD). This analysis included 668 individuals with
autosomal dominant tubulo-interstitial kidney disease due to UMOD mutations (ADTKD-UMOD) with clinical information available in addition to
determined rs4293393-mUMOD haplotype. An event was defined as end-stage kidney disease (ESKD) by starting dialysis, receiving a transplant,
or dying of kidney failure. Censoring occurred for death before ESKD or if the individual had not reached ESKD by the end of the study period.
There were only 41 individuals with the minor allele (G) in phase with mUMOD, resulting in insufficient power to detect a difference in survival.
ESRD, end-stage renal disease.
Table 4. Univariate models for individuals with ADTKD-UMOD
Parameter Observations (n) Events Reference category Hazard ratio C-statistic P value
Gender 675 342 Male 1.78 0.556 0.00028
rs4293393 minor variant in phase with mUMOD 668 337 A (major) 0.6885 0.507 0.36
rs4293393 minor variant in phase with wtUMOD 494 221 A (major) 0.6152 0.529 0.064
rs4293393 variant (at least 1 G allele present) 499 224 2 A alleles present 0.6943 0.528 0.13
mUMOD type 675 342 p.(H177_R185del) 0.561
Cysteine gain 0.9234 0.88
Cysteine loss 0.9995 1.0
Deletion/insertion 0.6369 0.3
Hydrophobic amino acid gain 0.3197 0.066
Proline gain 0.5321 0.13
Other 0.6155 0.15
In vitro score 393 198 1.5457 0.591 0.0022
Cysteine-rich domains 675 342 All other domains 0.8247 0.521 0.38
ADTKD-UMOD, autosomal dominant tubulo-interstitial kidney disease due to UMOD mutations; mUMOD, mutant uromodulin; wtUMOD, wild-type uromodulin.
Data combine Wake Forest and International cohorts.
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phase with mUMOD. A univariate model (Table 4)
was underpowered because of the presence of only 41
individuals with the minor allele phased with
mUMOD.
Scoring of UMOD Mutations
The trafficking of 35 mUMOD isoforms was charac-
terized in vitro (Figure 6, Table 2, Supplementary
Table S1, and Supplementary Figures S1 and S2).
MDCK and/or HEK293 cell lines were transfected with
expression vectors coding for different mUMODs. As
previously described,8 Western blot revealed 2 bands:
a lower molecular weight glycoform corresponding to
the uromodulin precursor in the ER that carries Endo
H-sensitive N-glycans, and a higher molecular weight
glycoform that carries post-Golgi, Endo H-resistant
type of glycans. The higher molecular weight form
corresponds to fully glycosylated, mature protein that
proceeded along the secretory pathway into post-Golgi
compartments (trans-Golgi network, secretory vesicles,
plasma membrane). UMOD mutation scoring was per-
formed by quantifying the ratio between low- and
high-molecular weight uromodulin glycoforms in cell
lysates, as a measure of trafficking defect. We
normalized these values to the ratio obtained for the
well-characterized, paradigm mutation C150S that
consistently shows strong ER retention. Mutations
were then subdivided into 4 distinct subgroups based
on the generated ratio before statistical correlation with
age of ESKD (Figure 6).
The different cellular phenotypes of mUMOD forms
and their severity were reproducible between indepen-
dent experiments (Supplementary Figure S1) and
conserved when expressed in different cell lines (e.g.,
HEK293 vs. MDCK) (Figure 6 and Supplementary
Figure S3), regardless of the expression system (tran-
sient or stable transfection) (Supplementary Figure S4).
UMOD Mutation Type and ESKD Survival
In univariate models, we found no difference in sur-
vival for the different mutation types but did show an
association with the in vitro score (Table 5 and ESKD
survival curve in Figure 7). For individuals with
mUMOD mutations that less hindered uromodulin
export to the cell surface (Group 1), renal survival was
significantly improved.
Multivariate Model
A multivariate model was then created based on the
genetic factors present in both cohorts. In the multi-
variate model, the presence of gender and in vitro score
provided the highest correlation (Table 6). We did not
find that the type of mutation was predictive of age of
ESKD (data not shown). There were no significant
interaction terms.
Analysis of Genetic and Clinical Factors for the
WF Cohort
Analysis of clinical and genetic factors was performed
on the WF cohort (Table 7). The presence of gout was
not associated with age of ESKD; however, a younger
age of gout for individuals who developed gout was
highly correlated with a younger age of ESKD (P <
0.0001). In univariate analysis (Table 7), maternal age
was highly associated with survival (P ¼ 0.0017),
whereas the paternal age was not (P ¼ 0.23). When
looking at subgroups, daughter and maternal age of
ESKD were most highly correlated, followed by son
and maternal age of ESKD (Supplementary Figures S1
and S2).
Multivariate clinical and genetic/clinical models
were then created using the WF cohort (Table 8). The
combination of gender and the family mean age of
ESKD were found to be the best predictors of survival.
There were no significant interaction terms.
DISCUSSION
This is the largest study that has been performed in
individuals with ADTKD-UMOD and is the result of a
large multinational collaboration that included 13
WT A39T C317Y C217G C135Y
Uromodulin100 kDa -
50 kDa -




Figure 6. Representative Western blot results from mutant UMOD
(mUMOD) in vitro experiments (Supplementary Methods). Western
blot analysis of HEK cells stably expressing wild-type (WT) or mutant
uromodulin isoforms. An in vitro score reflecting the severity of
trafficking defect was assigned to each mutation. The scoring was
performed by quantifying the ratio between endoplasmic reticulum
(ER)–retained and mature uromodulin glycoforms in cell lysates.
Table 5. Mean age of end-stage kidney disease in individuals with
ADTKD-UMOD according to in vitro score
In vitro score Observations (n) Age (mean ± SD)
1 42 59.4  11.0
2 56 50.4  11.0
3 90 48.5  12.1
4 59 47.2  11.7
Not available 179 46.3  13.1
ADTKD-UMOD, autosomal dominant tubulo-interstitial kidney disease due to UMOD
mutations.
Data include only individuals who reached end-stage kidney disease.
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different research groups. The age of ESKD onset in
individuals with ADTKD-UMOD ranges from 20 to
>70, and the goal of this study was to identify factors
associated with the highly variable age of ESKD onset.
The principal findings of the study included the
following: (i) the rs4293393 SNP in the mutant UMOD
promoter was not randomly distributed in families
with ADTKD-UMOD, with the minor allele (G) postu-
lated to produce decreased mUMOD significantly un-
derrepresented. (ii) An in vitro score that measured the
effect of the specific mUMOD mutation on uromodulin
trafficking was significantly correlated with kidney
survival. (iii) Women had significantly better renal
survival than men (hazard ratio 1.78, P < 0.001). (iv)
The maternal age of ESKD was significantly associated
with the child’s age of ESKD, particularly for women;
however, there remained significant variation. (v) A
younger age of gout was associated with a younger age
of ESKD. (vi) Twenty-eight new mutations were
described.
A major finding of the study was that the MAF of
the rs4293393 minor variant linked to mUMOD was
only 11% in affected families as opposed to the 18% to
20% found in the general population (P< 0.001) and as
opposed to the observed MAF of the rs4293393 allele in
phase with wild-type UMOD allele (17%). We postu-
late that the decreased allele frequency is due to
decreased mUMOD expression and hence a milder form
of ADTKD-UMOD associated with later age of ESKD
onset. Families with a later age of ESKD onset would be
less likely to be identified with ADTKD-UMOD and
less likely to be referred for evaluation and potential
entry into a disease registry. Because of the rs4293393
MAF of 19% in the general population, we anticipated
the need to collect a large number of affected in-
dividuals for the study. The further decrease in allele
Figure 7. End-stage kidney disease (ESKD) survival in individuals with autosomal dominant tubulo-interstitial kidney disease due to UMOD
mutations (ADTKD-UMOD) according in vitro score. This analysis included 393 individuals with 1 of the 35 UMOD mutations receiving an in vitro
score. An event was defined as ESKD by starting dialysis, receiving a transplant, or dying of kidney failure. Censoring occurred for death before
ESKD or if the individual had not reached ESKD by the end of the study period. ESRD, end-stage renal disease.
Table 6. Best-fit multivariate model for individuals with ADTKD-UMOD using gender and in vitro score
Parameter Observations (n) Events Reference category Hazard ratio C-statistic P value
Gender 393 198 Male 0.53 0.61 0.002
In vitro score 1.5 0.00085
ADTKD-UMOD, autosomal dominant tubulo-interstitial kidney disease due to UMOD mutations.
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frequency resulted in a marked decrease in the number
of individuals with the minor allele and hence a loss of
statistical power for the study. As the rs4293393 minor
SNP variant was not randomly distributed in the
ADTKD-UMOD population, we were not able to
perform a Mendelian randomization study. We did not
find a difference in survival between families with
major versus minor rs4293393-mUMOD haplotypes,
which may have been the result of lack of statistical
power, the fact that there was no difference, or the fact
that families with milder disease due to minor allele
rs4293393-mUMOD haplotypes were undetected.
We found that mutation class (e.g., loss or gain of
polarity or a cysteine residue) was not correlated with
the age of ESKD. This absence of correlation may have
been because of the conservative statistical analysis,
which adjusted for the large number of individuals in
different families. An in vitro score reflecting the
severity of the trafficking defect caused by specific
mUMOD mutations was found to be a promising pre-
dictor of the age of ESKD. In addition, this finding
points to enhanced transit of mUMOD through the ER
as a potential therapeutic approach. Supplementary
Table S1 provides information on all in vitro scores,
as well as the median age of ESKD for each mutation.
Based on the in vitro score, we would predict that the
type of mutation, but not the class of amino acid sub-
stitution (e.g., cysteine vs. noncysteine substitution)
does have an effect on ESKD survival. Other in-
vestigators have also studied the interaction between
genotype and phenotype in ADTKD-UMOD. Bollee and
colleagues3 reported on 109 patients from 45 families
with 37 distinct UMOD mutations and a median age of
ESKD of 54. These authors found a high intrafamilial
variability in the age of ESKD, with only a modest,
nonsignificant effect of the type of mutation on sur-
vival. In a review of the literature, Moskowitz and
colleagues4 identified 202 patients from 74 families with
59 different UMOD mutations and a median age of
ESKD of 56. Onset of ESKD was significantly earlier
with mutations in the epidermal growth factor domains
2 and 3 (range 45–52 years) compared with the
cysteine-rich domains (range 60–65 years) using a
shared frailty model. The in vitro score is novel and
should be considered a research test at this time.
Further development and validation are required to
assess its relevance as a clinical test that could be useful
in predicting the age of ESKD for individuals with de
novo mutations or from smaller families in which the
age of ESKD is not well characterized.
Male gender was a significant predictor of worse
renal outcomes, with a hazard ratio of 1.78, P < 0.001.
This was similar to the finding of Moskowitz et al.4 of
an increased risk of ESKD in men (hazard ratio 2.09,
P ¼ 0.04) in their cohort.
As part of this study, we were able to produce a
catalog of UMOD mutations, including the median age
of ESKD onset and in vitro score, which is included in
Supplementary Table S1 and available in an updated
form online at http://j.mp/2q7Fi8f. We believe that this
information will be helpful to clinicians working with
families with ADTKD-UMOD.
A primary weakness of this article was the lack of
power to better detect statistical differences among
groups, a major obstacle in the study of rare diseases.
Another weakness was the retrospective nature of the
study and limited clinical data from the international
cohort. For instance, information on gout was missing
from many of the historically affected individuals, and
this may have affected our ability to identify
Table 7. Univariate models for clinical characteristics for the WF cohort
Parameter Observations (n) Events Reference category Hazard ratio C-statistic P value
Weight 301 130 0.9967 0.545 0.23
BMI 300 130 0.9617 0.564 0.069
Smoking (active or former) 337 197 Nonsmoker 0.7185 0.533 0.17
Gout (y/n) 417 178 No 1.2549 0.52 0.29
Age of gout onset 209 110 0.9452 0.666 0.0000053
Parental age ESKD 229 101 0.9701 0.629 0.0045
Family mean age ESKD 429 217 0.9706 0.619 0.009
Mother’s age ESKD 111 53 0.9593 0.667 0.0017
Father’s age ESKD 114 47 0.9816 0.559 0.23
BMI, body mass index; ESKD, end-stage kidney disease; WF, Wake Forest.
Table 8. Multivariate model for the Wake Forest cohort
Parameter Observations (n) Events Reference category Hazard ratio C-statistic P value
Gender 429 217 Male 0.6380 0.634 0.0054
Family mean age ESKD 0.9591 <0.0001
ESKD, end-stage kidney disease.
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significant findings. Formation of a registry of in-
dividuals with ADTKD who contribute genetic sam-
ples, as well as clinical information, will be helpful to
overcome this obstacle in the future. In addition, we
were not able to explain fully the interfamilial and
intrafamilial variation in the age of ESKD onset.
In summary, we studied genetic and clinical factors
associated with the age of ESKD onset. An in vitro score
of mUMOD transit was a predictor of the age of onset of
ESKD, as was the presence of gout, age of gout onset, and
parental age of ESKD. The rs4293393 UMODminor allele,
associated with decreased uromodulin production, was
underrepresented in families with ADTKD-UMOD.
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